AI follow-up for DEL instead of resynthesis:

Faster results,
More diverse leads,
95% cost savings.

About DeepDELve

DeepDELve, developed since early 2019, is a highly-optimised deep learning pipeline for virtual screening. It allows DEL teams to identify target-binders within online catalogues instead of expensively resynthesising library hits. The pipeline yields very large numbers of more diverse leads, faster than resynthesis and at vastly lower cost.

By leveraging all hits within a DEL screen, DeepDELve extracts maximum value and allows the quick and inexpensive exploration of new chemical space. The pipeline can be integrated with any standard DEL collection.

24
hours
To train models and search all commercial catalogues (including Enamine REAL lead-like space).
3
days
To receive the fastest catalogue compounds.
95%
lower
Cost per confirmed lead, compared to resynthesis.

Partners

In addition to large, medium, and small pharmaceutical companies currently undisclosed.

News

5 November 2021
Cambridge Molecular and HitGen Announce Strategic Partnership
All News
background picture

Contact Us

general@cambridgemolecular.ai

Cambridge Molecular Ltd
The Bradfield Centre
184 Cambridge Science Park
Cambridge CB4 0GA
England

© 2019 Cambridge Molecular Ltd